DIPROSONE LOTION

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE)

Beschikbaar vanaf:

ORGANON CANADA INC.

ATC-code:

D07AC01

INN (Algemene Internationale Benaming):

BETAMETHASONE

Dosering:

0.05%

farmaceutische vorm:

LOTION

Samenstelling:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05%

Toedieningsweg:

TOPICAL

Eenheden in pakket:

15G/50G

Prescription-type:

Prescription

Therapeutisch gebied:

ANTI-INFLAMMATORY AGENTS

Product samenvatting:

Active ingredient group (AIG) number: 0106299002; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2011-02-08

Productkenmerken

1
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
DIPROSONE
®
BETAMETHASONE DIPROPIONATE CREAM, ORGANON STANDARD,
0.05% W/W BETAMETHASONE (AS DIPROPIONATE)
BETAMETHASONE DIPROPIONATE OINTMENT, ORGANON STANDARD,
0.05% W/W BETAMETHASONE (AS DIPROPIONATE)
BETAMETHASONE DIPROPIONATE LOTION, USP,
0.05% W/W BETAMETHASONE (AS DIPROPIONATE)
Topical Corticosteroid
ORGANON CANADA INC.
16766 route Transcanadienne
Kirkland, Quebec
H9H 4M7
www.organon.ca
Date of Initial Approval:
NOV 07, 1974
Date of Revision:
April 7, 2021
Submission Control No.: 249884
2
TABLE OF CONTENTS
TABLE OF CONTENTS
..............................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
1
INDICATIONS
..................................................................................................................3
1.1
Pediatrics
....................................................................................................................3
1.2
Geriatrics
....................................................................................................................3
2
CONTRAINDICATIONS
.................................................................................................3
3
DOSAGE AND ADMINISTRATION
.............................................................................3
3.1
Dosing Considerations
...............................................................................................3
3.2
Administration
...........................................................................................................4
4
MISSED DOSE
..................................................................................................................4
5
OVERDOSAGE
.................................................................................................................4
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................4
7
WARNINGS AND PRECAUTIONS
.........